The US Food and Drug Administration’s revised draft guidance on scientific communications to health care providers about a medical product's unapproved uses did not dampen industry’s decade-long objections to its regulation of such speech.
The Medical Information Working Group, comprised of nine pharma companies, said the guidance exceeds the statutory and constitutional limits on the agency’s authority and is likely to chill a significant amount
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?